Receptos Provides Update on Progress of Lead Product Candidate RPC1063

Published: Jun 05, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, June 5, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, confirmed today that RPC1063, its selective sphingosine-1- phosphate 1 receptor (S1P1R) modulator, has successfully completed a study of the heart's electrical conduction system, known as a "thorough QT/QTc" (TQT) study. RPC1063 is currently being studied in randomized Phase 2 trials for the treatment of relapsing multiple sclerosis (RMS) and ulcerative colitis (UC).

Help employers find you! Check out all the jobs and post your resume.

Back to news